

FIGURE 4. Involvement of P-selectin/PSGL-1 in reactivation of HIV-1 replication by FDC. *A* and *B*, U1 cells (1×10^5 cells/well) were cocultured with FDCs (1×10^4 cells/well) for 3 days. The mRNA levels of the indicated genes were then measured by quantitative RT-PCR. Labels inside parentheses indicate counterpart ligand or receptor molecules. *C–E*, U1 cells (1×10^5 cells/well) were cocultured with FDCs (1×10^4 cells/well) in the presence of BAY 11-7082 ($1 \mu\text{M}$) for 3 days and the levels of PSGL-1 in these cells were then analyzed by quantitative RT-PCR (*C*). Cell surface PSGL-1 was analyzed by flow cytometry using an anti-PSGL-1 Ab (*D*). M1 denotes the range of positive cell populations. *E*, P-selectin expression in FDCs analyzed by quantitative RT-PCR. *F*, U1 cells (1×10^5 cells/well) were untreated or pretreated with either PSGL-1 or ICAM-1 Ab for 1 h. Cells were then cocultured with FDCs (1×10^4 cells/well) for 3 days followed by measurement of p24. *G*, U1 cells (1×10^5 cells/well) were transfected with either control or PSGL-1 siRNA (final 6 nM) by Nucleofector according to the manufacturer's instructions. Cells were then cocultured with FDCs (1×10^4 cells/well) for 3 days followed by Western blot analysis with the indicated Abs. Numerical values below the blots indicate p24 signal intensities normalized by α -tubulin intensity derived by densitometry. The data shown are the average \pm SD of three independent experiments (*, $p \leq 0.05$ and **, $p \leq 0.01$ by the Student *t* test).

recruited and bind directly to the HIV-1 LTR (31–33). To determine the identity of the *cis*-regulatory element(s) within the HIV-1 LTR that are the targets of FDC-mediated transcriptional activa-

tion, we examined various 5'-deletion mutants of these region as described in Fig. 3C (34). Coculturing of U1 cells with FDCs resulted in the activation of CD12 and CD23 reporter constructs

that harbor a NF- κ B-binding sequence. However, the CD52 and CD54 constructs lacking this NF- κ B consensus site were not activated, suggesting the involvement of NF- κ B in the HIV-1 replication response (Fig. 3D). Consistent with this notion, the reporter construct CD12 that contains a site-directed mutation within the NF- κ B binding site, CD12m κ B, was not responsive to FDC stimulation. These results together indicate that the stimulation of HIV-1 in infected cells by FDCs is mediated via the activation of the HIV-1 LTR via NF- κ B.

To further address this in terms of biological function, cells were treated with the NF- κ B inhibitor BAY 11-7082 to further delineate the role of NF- κ B in FDC-mediated HIV-1 replication. Treatment with BAY 11-7082 significantly suppressed HIV-1 production from U1 cells, even when growing in coculture with FDCs (Fig. 3E), although the viability of both cell types was not significantly affected by this exposure (data not shown). Taken together, our data thus indicate that intercellular communication pathways triggered by FDCs can promote and augment HIV-1 production in infected cells via NF- κ B activation.

We next investigated whether NF- κ B is in fact activated in FDCs as well as in U1 cells under coculture conditions. Consistent with our above gene reporter data, NF- κ B activation was confirmed in U1 cells as revealed by the phosphorylation status of NF- κ B p65 and I κ B α (Fig. 3F). Interestingly, parallel experiments showed NF- κ B activation in FDCs also in our coculture system, as revealed by immunoblotting with phospho-specific Abs (Fig. 3F). Furthermore, fractionation analysis demonstrated that the nuclear p65 (RelA) levels were significantly enhanced in both U1 and FDCs, indicating the nuclear accumulation of activated NF- κ B (Fig. 3F). Parallel kinetic analysis revealed that NF- κ B activation in U1 cells was initiated at 12 h and persisted for at least 48 h (Fig. 3G). These findings thus support our contention that cell-cell interactions between FDCs and U1 cells results in the constitutive activation of NF- κ B in both cell types and that this is likely to be involved in the amplification of HIV-1 replication signals.

FDCs activate HIV-1 production via a P-selectin-PSGL-1 interaction

We were prompted to examine whether NF- κ B up-regulates a specific cell surface ligand and its cognate receptor in FDCs and HIV-1-infected monocytic cells, eventually contributing to the amplification of HIV-1 replication signals via NF- κ B activation. To this end, we examined the expression of different cell surface ligands and their cognate receptors which are known to be regulated by NF- κ B. We chose three ligand/receptor combinations based upon a database search, ICAM-1/CD11b, VCAM-1/CD49d, and P-selectin/PSGL-1, and the expression of these molecules was analyzed by quantitative RT-PCR. Although the mRNA levels of ICAM-1 and VCAM-1 were not significantly altered upon stimulation, transcripts for P-selectin (CD62P/SLBP) were dramatically increased in FDCs (Fig. 4A). Interestingly, transcripts for the cognate receptor for P-selectin, PSGL-1, were found to be significantly up-regulated in U1 cells grown in coculture with the FDCs (Fig. 4B), but this was not the case for the CD11b and CD49d receptors. Quantitative RT-PCR and FACS analysis revealed that treatment with the NF- κ B inhibitor BAY11-7082 significantly inhibited the increase of PSGL-1 mRNA expression and, consequently the cell surface expression of PSGL-1, in U1 cells cocultured with FDCs (Fig. 4, C and D). This suggested a crucial role for NF- κ B signaling in the induction of PSGL-1 during this coculture in HIV-1-infected cells. Likewise, we found that BAY11-7082 treatment also decreased the induction of P-selectin mRNA in FDCs, indicating that the NF- κ B activation in FDCs could play




FIGURE 5. Syk is a mediator of P-selectin/PSGL-1 signaling for HIV-1 replication in U1 cells. *A* and *B*, U1 cells (1×10^5 cells/well) were untreated or pretreated with either ER-27319 (30 μ M) or JNK inhibitor II (1 μ M) for 1 h. Cells were then cocultured with FDCs (1×10^4 cells/well) for 3 days in the presence or absence of inhibitor. Cells were collected and subjected to immunoblotting analysis for phosphorylated Syk (Tyr³⁵²), unmodified Syk, and α -tubulin (*A*). The numbers below the blot indicate the band intensity ratios. Cell supernatants were assayed for measurement of p24 (*B*). The data shown are the average \pm SD of two independent experiments (*, $p \leq 0.05$ and **, $p \leq 0.01$ by the Student *t* test).

a crucial role in the induction of P-selectin during the coculture with HIV-1-infected monocytic cells (Fig. 4E).

Next, to test the biological significance of a P-selectin-PSGL-1 interaction in terms of HIV-1 induction in our FDC coculture system, U1 cells were pretreated with blocking Ab against PSGL-1 before setting up these cultures. Treatment with PSGL-1 Ab, but not an ICAM-1 Ab, specifically suppressed HIV-1 production in a dose-dependent manner (Fig. 4F). Consistent with this result, targeted disruption of PSGL-1 by specific siRNA significantly decreased HIV-1 production in U1 cells coculturing with FDCs (Fig. 4G). These results together indicate that a juxtacrine signaling mechanism mediated by PSGL-1/P-selectin underlies the activation of HIV-1 replication in infected monocytic cells stimulated by FDCs.

Syk acts as a downstream effector of PSGL-1 during HIV-1 replication

Several previous reports have demonstrated that the cytoplasmic domain of PSGL-1 can directly interact with a Src family kinase, the Syk (35). Syk consists of two N-terminal Src homology 2 domains, which bind phosphorylated ITAM sequences, and a C-terminal tyrosine kinase domain (35–37). The phosphorylation of Syk at Tyr³⁵² has been shown to be a hallmark of its activation. Indeed, phosphorylated Syk was found in our present analyses to be significantly increased in U1 cells during their cocultivation with FDCs (Fig. 5A).

To next examine the possible biological functions of Syk during HIV-1 replication, we used a specific inhibitor of the molecule ER-27319 (29, 30) in our FDC cocultures. Treatment with ER-27319 significantly decreased HIV-1 production and this was accompanied by a reduction in the phosphorylated Syk levels in U1




FIGURE 6. Inhibition of the PSGL-1/Syk pathway abrogates FDC-induced HIV-1 replication in primary monocytes. *A* and *B*. Primary human monocytes were separated from three healthy donors as indicated in *Materials and Methods* and these cells were then treated with 3 μ g/ml PHA for 3 days. After stimulation, the cells (1×10^5 cells/well) were infected with HIV-1_{JR-FL} (MOI = 0.05) for 24 h and subsequently cocultured with FDCs (1×10^4 cells/well) in the presence of PSGL-1 Ab (25 μ g/ml; *A*) or ER-27319 (30 μ M; *B*) at 14 days, followed by measurement of p24 (*, $p \leq 0.05$ and **, $p \leq 0.01$ by the Student *t* test).

cells (Fig. 5), whereas JNK inhibitor II had no such effects. These results indicate that the juxtacrine signaling between FDCs and HIV-1-infected monocytic cells mediated by P-selectin/PSGL-1 results in the activation of Syk, which serves as a mediator of the function of NF- κ B activation in the HIV-1 replication pathway.

PSGL-1 and Syk inhibition blocks FDC-induced HIV-1 replication in primary monocytes

Finally, we addressed whether FDCs can also activate HIV-1 production in infected primary cells via P-selectin/PSGL-1 pathway, in this case human primary monocytes from healthy donors that had subsequently been exposed to HIV-1_{JR-FL}. At 24 h after viral infection, the primary monocytes were cocultured with FDCs in the presence or absence of either PSGL-1 Ab or the Syk inhibitor ER-27319. Both of these treatments significantly inhibited HIV-1 production in the primary monocytes in a manner similar to U1 cells (Fig. 6). These results indicate that similar to U1 cells, the PSGL-1/Syk signaling is likely to be a major pathway mediating FDC-induced HIV-1 replication in primary monocytes.

Discussion

Previous studies have indicated that HIV-1 infection is largely confined to the GCs of secondary lymph nodes where FDCs commonly reside (15–17). This microenvironment could thus provide the site for highly productive HIV-1 infection whereby FDCs might execute “on-switch” signaling to increase HIV replication. Furthermore, cell-cell infection appears to be far more efficient for

viral spread than cell-free virus infection (38, 39). We here report that FDCs can facilitate HIV-1 replication in adjacent infected monocytes/macrophages via a cell-cell interaction mechanism.

FDCs have been shown to interact with B or CD4⁺ T cells in the GCs of normal lymph nodes (16, 17, 20). It is also reported that in tonsils, CD150 (SLAMF6)⁺ monocytes were localized not only in T cell areas, but also within GCs, suggesting they play a role in B cell activation (40). Moreover, substantial numbers of HIV-1-infected macrophages were observed in GCs during the course of HIV infection (41). Thus, FDCs can interact with HIV-1-infected monocytes or macrophages under these conditions during HIV-1 infection. Furthermore, the dysfunctional FDC network is observed in secondary lymph nodes of lymphadenopathy, where the degeneration of the FDC network is usually seen following highly active antiretroviral therapy or administration of therapeutic vaccine in HIV or SIV infection (42–45). One of the most common histological features of HIV-1-associated lymphadenopathy is hyperplastic lymphoid follicles that subsequently undergoes folliculolysis, in which FDCs can be scattered to the extra-GC within the lymph nodes such as cortical sinuses and mantle bodies (46, 47). Our results with immunohistochemical analysis indicate that FDCs reside with various types of HIV-1-infected cells including monocytes or macrophages in lymphoid organs of HIV-1-associated lymphadenopathy (supplemental Fig. 1). Therefore, our current proposed model for cell-cell interaction between FDCs and HIV-1-infected monocytic cells may reflect the biological or pathological aspects of the natural HIV infection in vivo. However, we could not determine the specific cell surface molecules for activating HIV-1 replication via the cell-cell interaction in vivo. Moreover, it is not well confirmed whether a multitude of other cells, cytokines, and other factors in vivo could influence the cell-cell interaction observed in our in vitro coculture system. Further careful analysis should be performed using human tissues as well as a humanized mouse model inoculated with HIV-1-infected human cells.

We clearly demonstrated here that FDCs, derived from human tonsils, can enhance HIV-1 production in infected monocytic cells in a coculture system. This enhancement requires direct cell-cell interactions via a juxtacrine signaling pathway that is mediated by P-selectin/PSGL-1. Our results are summarized as follows: 1) FDCs can activate HIV-1 replication in infected cells through cell-cell interactions; 2) HIV-1 replication is activated at the transcriptional level and is accompanied by the activation of the HIV-1 LTR through NF- κ B; 3) P-selectin expression in FDCs and the up-regulation of its cognate receptor PSGL-1 in HIV-1-infected monocytes cells are facilitated via NF- κ B activation; 4) the pathways leading to HIV-1 induction in cell lines also function in human primary monocytes and macrophages infected with HIV-1; and 5) selective inhibitors of PSGL-1 or Syk can efficiently block HIV-1 production in U1 and primary monocytes. These data together indicate for the first time that FDCs are a potent inducer of HIV-1 replication in surrounding infected monocytes and macrophages and that PSGL-1/Syk signaling plays a crucial role in this induction of HIV-1.

Very recently, Thacker et al. (26) reported a similar but distinct role of FDCs in the induction of HIV-1 replication in CD4⁺ T cells obtained from PBMCs and GCs. We also confirmed that FDCs could stimulate HIV-1 replication in MOLT-4 T cells (23) as well as in primary CD4⁺ T cells (data not shown). However, FDC-induced HIV-1 replication in CD4⁺ T cells might be mediated by a distinct mechanism from HIV-1-infected monocytic cells since the involvement of the PSGL-1/Syk pathway in CD4⁺ T cells was found to be not prominent (K. Ohba, A. Ryo, and N. Yamamoto, unpublished observation). Therefore, the molecular mechanism for

FDCs to stimulate HIV-1 replication in surrounding infected cells could be attributable to cell type specific.

Intercellular interactions via a ligand/receptor juxtacrine signaling system has been implicated in several virus infections. Tsukamoto et al. (48) reported that the juxtacrine function of the IL-15/IL-15 receptor system in human B cell lines might play a role in the infectivity of EBV (48). Pilotti et al. (49) have demonstrated a crucial protective role for CCL3L1/CCL3 (MIP-1 α /LD78 α) signals in both HIV infection and subsequent disease progression. These intercellular communication processes may play an important role in the sustained infection of viruses in different microenvironments within lymphoid organs. Further careful analyses will be required in the future to elucidate the variety of intercellular communication systems that may operate during HIV-1 infection.

There is now some evidence for a role of PSGL-1 as a signal-transmitting receptor in neutrophils (50), monocytes (51), and T lymphocytes (52). This molecule has been reported to associate with Syk through its interaction with moesin and promotes the tyrosine phosphorylation and thus the activation of Syk (35). In addition, signals elicited through PSGL-1/Syk can induce the activation of downstream effectors such as ERK, c-Fos, and NF- κ B (53). The activation of NF- κ B via PSGL-1 has also been demonstrated in platelet-stimulated monocytes, although the details of the molecular pathways leading to NF- κ B activation in this manner have not yet been elucidated (51). Consistent with this result also, we found from our current analyses that PSGL-1/Syk signaling can activate NF- κ B. This observation suggests a linkage between PSGL-1 signaling and HIV-1 replication through the activation of NF- κ B.

Recently, Gilbert et al. (54) have reported that Src and Syk tyrosine kinases play important roles in the spread of HIV-1 from immature monocyte-derived DCs to CD4⁺ T cells. They found that these kinases play a suppressive role in virus transfer in vitro probably by inhibiting the formation of the virological synapse. However, it has not been well characterized whether these signaling molecules contribute to the cell-cell interaction between HIV-1-infected cells and adjacent noninfected cells for virus replication. We showed in this current study that the activation of Syk through the PSGL-1 positively regulates HIV-1 replication in infected monocytic cells. Thus, Syk could be involved at multiple points in HIV-1 infection and its role could be dependent on each step of HIV-1 life cycle.

In summary, we demonstrate in our current study that FDCs are a potent activator of HIV-1 replication in surrounding infected monocytic cells. Furthermore, the PSGL-1/Syk pathway is important for this activation of HIV-1 replication. These results shed valuable new light on our understanding of the natural progression of HIV-1 infection over the long term and could provide a means for designing novel therapeutic interventions against AIDS and related disorders.

Acknowledgments

We thank S. Yamaoka and W. Sugiura for helpful discussions and H. Shimura, N. Sakamaki, C. Matsubara, M. Tanaka, and H. Soeda for technical assistance.

Disclosures

The authors have no financial conflict of interest.

References

- Stevenson, M. 2003. HIV-1 pathogenesis. *Nat. Med.* 9: 853–860.
- Pope, M., and A. T. Haase. 2003. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. *Nat. Med.* 9: 847–852.
- Matsuyama, T., Y. Hamamoto, T. Okamoto, K. Shimotohno, N. Kobayashi, and N. Yamamoto. 1988. Tumour necrosis factor and HIV: a note of caution. *Lancet* 2: 1364.
- Matsuyama, T., N. Kobayashi, and N. Yamamoto. 1991. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? *AIDS* 5: 1405–1417.
- Kinter, A., J. Arthos, C. Cicala, and A. S. Fauci. 2000. Chemokines, cytokines and HIV: a complex network of interactions that influence HIV pathogenesis. *Immunol. Rev.* 177: 88–98.
- Kedzierska, K., S. M. Crowe, S. Turville, and A. L. Cunningham. 2003. The influence of cytokines, chemokines and their receptors on HIV-1 replication in monocytes and macrophages. *Rev. Med. Virol.* 13: 39–56.
- Pantaleo, G., C. Graziosi, J. F. Demarest, L. Butini, M. Montroni, C. H. Fox, J. M. Orenstein, D. P. Kotler, and A. S. Fauci. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. *Nature* 362: 355–358.
- Pierson, T., J. McArthur, and R. F. Siliciano. 2000. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. *Annu. Rev. Immunol.* 18: 665–708.
- Han, Y., M. Wind-Rotolo, H. C. Yang, J. D. Siliciano, and R. F. Siliciano. 2007. Experimental approaches to the study of HIV-1 latency. *Nat. Rev. Microbiol.* 5: 95–106.
- Pauza, C. D. 1988. HIV persistence in monocytes leads to pathogenesis and AIDS. *Cell. Immunol.* 112: 414–424.
- Igarashi, T., C. R. Brown, Y. Endo, A. Buckler-White, R. Plishka, N. Bischofberger, V. Hirsch, and M. A. Martin. 2001. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4⁺ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. *Proc. Natl. Acad. Sci. USA* 98: 658–663.
- Moser, B., and P. Loetscher. 2001. Lymphocyte traffic control by chemokines. *Nat. Immunol.* 2: 123–128.
- Cahalan, M. D., and G. A. Gutman. 2006. The sense of place in the immune system. *Nat. Immunol.* 7: 329–332.
- Bieniasz, P. D. 2004. Intrinsic immunity: a front-line defense against viral attack. *Nat. Immunol.* 5: 1109–1115.
- Allen, C. D., T. Okada, and J. G. Cyster. 2007. Germinal-center organization and cellular dynamics. *Immunity* 27: 190–202.
- Szakai, A. K., Y. Aydar, P. Balogh, and J. G. Tew. 2002. Molecular interactions of FDCs with B cells in aging. *Semin. Immunol.* 14: 267–274.
- van Nierop, K., and C. de Groot. 2002. Human follicular dendritic cells: function, origin and development. *Semin. Immunol.* 14: 251–257.
- Victoratos, P., J. Lagnel, S. Tzima, M. B. Alimzhanov, K. Rajewsky, M. Pasparakis, and G. Kollias. 2006. FDC-specific functions of p55TNFR and IKK2 in the development of FDC networks and of antibody responses. *Immunity* 24: 65–77.
- Tew, J. G., J. Wu, M. Fakher, A. K. Szakai, and D. Qin. 2001. Follicular dendritic cells: beyond the necessity of T-cell help. *Trends Immunol.* 22: 361–367.
- Li, L., and Y. S. Choi. 2002. Follicular dendritic cell-signaling molecules required for proliferation and differentiation of GC-B cells. *Semin. Immunol.* 14: 259–266.
- Lee, I. Y., E. M. Ko, S. H. Kim, D. I. Jeoung, and J. Choe. 2005. Human follicular dendritic cells express prostacyclin synthase: a novel mechanism to control T cell numbers in the germinal center. *J. Immunol.* 175: 1658–1664.
- Keele, B. F., L. Tazi, S. Gartner, Y. Liu, T. B. Burgon, J. D. Estes, T. C. Thacker, K. A. Crandall, J. C. McArthur, and G. F. Burton. 2008. Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. *J. Virol.* 82: 5548–5561.
- Taruishi, M., K. Terashima, Z. Dewan, N. Yamamoto, S. Ikeda, D. Kobayashi, Y. Eishi, M. Yamazaki, T. Furusaka, M. Sugimoto, et al. 2004. Role of follicular dendritic cells in the early HIV-1 infection: in vitro model without specific antibody. *Microbiol. Immunol.* 48: 693–702.
- Burton, G. F., B. F. Keele, J. D. Estes, T. C. Thacker, and S. Gartner. 2002. Follicular dendritic cell contributions to HIV pathogenesis. *Semin. Immunol.* 14: 275–284.
- Grouard, G., and E. A. Clark. 1997. Role of dendritic and follicular dendritic cells in HIV infection and pathogenesis. *Curr. Opin. Immunol.* 9: 563–567.
- Thacker, T. C., X. Zhou, J. D. Estes, Y. Jiang, B. F. Keele, T. S. Elton, and G. F. Burton. 2009. Follicular dendritic cells and human immunodeficiency virus type 1 transcription in CD4⁺ T cells. *J. Virol.* 83: 150–158.
- Folks, T. M., J. Justement, A. Kinter, C. A. Dinarello, and A. S. Fauci. 1987. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. *Science* 238: 800–802.
- Watanabe, S., K. Terashima, S. Ohta, S. Horibata, M. Yajima, Y. Shiozawa, M. Z. Dewan, Z. Yu, M. Ito, T. Morio, et al. 2007. Hematopoietic stem cell-engrafted NOD/SCID/IL2R γ null mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses. *Blood* 109: 212–218.
- Moriya, K., J. Rivera, S. Odum, Y. Sakuma, K. Muramoto, T. Yoshiuchi, M. Miyamoto, and K. Yamada. 1997. ER-27319, an acridone-related compound, inhibits release of antigen-induced allergic mediators from mast cells by selective inhibition of Fc ϵ receptor 1-mediated activation of Syk. *Proc. Natl. Acad. Sci. USA* 94: 12539–12544.
- Andrews, R. P., C. L. Kopley, L. Youssef, B. S. Wilson, and J. M. Oliver. 2001. Regulation of the very late antigen-4-mediated adhesive activity of normal and nonreleaser basophils: roles for Src, Syk, and phosphatidylinositol 3-kinase. *J. Leukocyte Biol.* 70: 776–782.
- Cullen, B. R. 1991. Regulation of HIV-1 gene expression. *FASEB J.* 5: 2361–2368.

32. Rohr, O., C. Marban, D. Aunis, and E. Schaeffer. 2003. Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells. *J. Leukocyte Biol.* 74: 736–749.
33. Okamoto, T., T. Matsuyama, S. Mori, Y. Hamamoto, N. Kobayashi, N. Yamamoto, S. F. Josephs, F. Wong-Staal, and K. Shimotohno. 1989. Augmentation of human immunodeficiency virus type 1 gene expression by tumor necrosis factor α . *AIDS Res. Hum Retroviruses* 5: 131–138.
34. Takada, N., T. Sanda, H. Okamoto, J. P. Yang, K. Asamitsu, L. Sarol, G. Kimura, H. Uranishi, T. Tetsuka, and T. Okamoto. 2002. RelA-associated inhibitor blocks transcription of human immunodeficiency virus type 1 by inhibiting NF- κ B and Sp1 actions. *J. Virol.* 76: 8019–8030.
35. Urzainqui, A., J. M. Serrador, F. Viedma, M. Yanez-Mo, A. Rodriguez, A. L. Corbi, J. L. Alonso-Lebrero, A. Luque, M. Deckert, J. Vazquez, and F. Sanchez-Madrid. 2002. ITAM-based interaction of ERM proteins with Syk mediates signaling by the leukocyte adhesion receptor PSGL-1. *Immunity* 17: 401–412.
36. Fodor, S., Z. Jakus, and A. Mocsai. 2006. ITAM-based signaling beyond the adaptive immune response. *Immunol. Lett.* 104: 29–37.
37. Underhill, D. M., and H. S. Goodridge. 2007. The many faces of ITAMs. *Trends Immunol.* 28: 66–73.
38. Dimitrov, D. S., R. L. Willey, H. Sato, L. J. Chang, R. Blumenthal, and M. A. Martin. 1993. Quantitation of human immunodeficiency virus type 1 infection kinetics. *J. Virol.* 67: 2182–2190.
39. Chancey, C. J., K. V. Khanna, J. F. Seegers, G. W. Zhang, J. Hildreth, A. Langan, and R. B. Markham. 2006. Lactobacilli-expressed single-chain variable fragment (scFv) specific for intercellular adhesion molecule 1 (ICAM-1) blocks cell-associated HIV-1 transmission across a cervical epithelial monolayer. *J. Immunol.* 176: 5627–5636.
40. Farina, C., D. Theil, B. Semlinger, R. Hohlfeld, and E. Meinel. 2004. Distinct responses of monocytes to Toll-like receptor ligands and inflammatory cytokines. *Int. Immunol.* 16: 799–809.
41. Eitner, F., Y. Cui, G. Grouard-Vogel, K. L. Hudkins, A. Schmidt, T. Birkebak, M. B. Agy, S. L. Hu, W. R. Morton, D. M. Anderson, et al. 2000. Rapid shift from virally infected cells to germinal center-retained virus after HIV-2 infection of macaques. *Am. J. Pathol.* 156: 1197–1207.
42. Gray, C. M., J. Lawrence, E. A. Ranheim, M. Vierra, M. Zupancic, M. Winters, J. Altman, J. Montoya, A. Zolopa, J. Schapiro, et al. 2000. Highly active anti-retroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8⁺ T cells. *AIDS Res. Hum Retroviruses* 16: 1357–1369.
43. Lu, W., X. Wu, Y. Lu, W. Guo, and J. M. Andrieu. 2003. Therapeutic dendritic-cell vaccine for simian AIDS. *Nat. Med.* 9: 27–32.
44. Schmitz, J., J. van Lunzen, K. Tenner-Racz, G. Grossschupff, P. Racz, H. Schmitz, M. Dietrich, and F. T. Hufert. 1994. Follicular dendritic cells retain HIV-1 particles on their plasma membrane, but are not productively infected in asymptomatic patients with follicular hyperplasia. *J. Immunol.* 153: 1352–1359.
45. Zhang, Z. Q., T. Schuler, W. Cavert, D. W. Notermans, K. Gebhard, K. Henry, D. V. Havlir, H. F. Gunthard, J. K. Wong, S. Little, et al. 1999. Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection. *Proc. Natl. Acad. Sci. USA* 96: 5169–5172.
46. Baroni, C. D., and S. Uccini. 1990. Lymph nodes in HIV-positive drug abusers with persistent generalized lymphadenopathy: histology, immunohistochemistry, and pathogenetic correlations. *Prog. AIDS Pathol.* 2: 33–50.
47. Houn, H. Y., A. A. Pappas, and E. M. Walker, Jr. 1990. Lymph node pathology of acquired immunodeficiency syndrome (AIDS). *Ann. Clin. Lab. Sci.* 20: 337–342.
48. Tsukamoto, K., Y. C. Huang, W. C. Dorsey, B. Carns, and V. Sharma. 2006. Juxtacrine function of interleukin-15/interleukin-15 receptor system in tumour derived human B-cell lines. *Clin. Exp. Immunol.* 146: 559–566.
49. Pilotti, E., L. Elvirio, E. Vicenzi, U. Bertazzoni, M. C. Re, S. Allibardi, G. Poli, and C. Casoli. 2007. Postgenomic up-regulation of CCL3L1 expression in HTLV-2-infected persons curtails HIV-1 replication. *Blood* 109: 1850–1856.
50. Hidari, K. I., A. S. Weyrich, G. A. Zimmerman, and R. P. McEver. 1997. Engagement of P-selectin glycoprotein ligand-1 enhances tyrosine phosphorylation and activates mitogen-activated protein kinases in human neutrophils. *J. Biol. Chem.* 272: 28750–28756.
51. Weyrich, A. S., T. M. McIntyre, R. P. McEver, S. M. Prescott, and G. A. Zimmerman. 1995. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor- α secretion: signal integration and NF- κ B translocation. *J. Clin. Invest.* 95: 2297–2303.
52. Damle, N. K., K. Klussman, M. T. Dietsch, N. Mohagheghpour, and A. Aruffo. 1992. GMP-140 (P-selectin/CD62) binds to chronically stimulated but not resting CD4⁺ T lymphocytes and regulates their production of proinflammatory cytokines. *Eur. J. Immunol.* 22: 1789–1793.
53. Tada, J., M. Omine, T. Suda, and N. Yamaguchi. 1999. A common signaling pathway via Syk and Lyn tyrosine kinases generated from capping of the sialomucins CD34 and CD43 in immature hematopoietic cells. *Blood* 93: 3723–3735.
54. Gilbert, C., C. Barat, R. Cantin, and M. J. Tremblay. 2007. Involvement of Src and Syk tyrosine kinases in HIV-1 transfer from dendritic cells to CD4⁺ T lymphocytes. *J. Immunol.* 178: 2862–2871.



Contents lists available at ScienceDirect

Biochemical and Biophysical Research Communications

journal homepage: www.elsevier.com/locate/ybbrc

The prolyl isomerase Pin1 stabilizes the human T-cell leukemia virus type 1 (HTLV-1) Tax oncoprotein and promotes malignant transformation

Soo-Jin Jeong, Akihide Ryo*, Naoki Yamamoto*

AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan

ARTICLE INFO

Article history:

Received 6 February 2009

Available online 11 February 2009

Keywords:

Pin1

Tax

Protein stability

Ubiquitination

Transformation

ABSTRACT

The HTLV Tax protein is crucial for viral replication and malignant transformation. We investigated the possible role of peptidyl prolyl isomerase Pin1 in the positive regulation of the human T-cell leukemia virus type 1 Tax. Pin1 is highly expressed in adult T-cell leukemia (ATL) cells expressing Tax protein and forced expression of Pin1 in turn increases the Tax protein expression. Pin1 prolonged the protein half-life of Tax by suppressing the ubiquitination and subsequent lysosomal degradation of Tax. Pin1 interacts with phosphorylated Tax on its Ser160-Pro motif at the mitotic phase. Finally, we found that Pin1 plays a supporting role in Tax-mediated cell transformation. Our current study demonstrates an important role for Pin1 in the post-translational regulation of Tax and suggests that the targeting of Pin1 may offer a new insight into the pathogenesis of HTLV-1 related diseases.

© 2009 Elsevier Inc. All rights reserved.

Introduction

The peptidyl-prolyl *cis/trans* isomerase (PPIase) Pin1 binds only to phospho-Ser/Thr-Pro motifs on its substrate proteins, thereby catalyzing the *cis/trans* isomerization of the peptide bond and acting as a post-phosphorylation catalyst in the regulation of protein function [1]. Pin1 is highly expressed in various cancers and its deregulation of Pin1 may play a pivotal role in these diseases [1,2]. For instance, it has been reported that Pin1 positively regulates both colorectal and mammary tumorigenesis by increasing β -catenin and cyclin D1 expression [3]. Also, our recent studies have demonstrated that Pin1 acts as a putative anti-apoptotic molecule by the negative regulating Daxx in malignant tumor cells [4].

Human T-cell leukemia virus type 1 (HTLV-1) is the etiologic agent of the aggressive and fatal malignancy of CD4+ lymphocytes known as adult T-cell leukemia (ATL) [5]. During the carrier state in HTLV-1-mediated malignancies such as ATL, the oncoprotein Tax has been shown to play an essential role in the cell proliferation and oncogenesis [6]. Tax is a 40-kDa viral regulatory protein and plays critical roles in the activation of various cellular genes and for viral gene expression, replication and transformation [7]. Tax is a phosphoprotein with a predominately nuclear subcellular localization that accomplishes multiple functions via protein-protein interactions [8].

In our current study, we have investigated the regulation of Tax by Pin1 through phosphorylation-dependent prolyl isomerization. Our results demonstrate that Pin1 physically interacts with Tax,

especially during the mitotic phase there by inhibiting both the ubiquitination and the lysosomal degradation of Tax. We also demonstrate that the phosphorylation of Tax on Ser160-Pro motif by mitotic kinase(s) is crucial for both its interaction with Pin1 and its prolonged stabilization. Of importance, a soft agar colony transformation assay using CTLL-2 cells demonstrated that Pin1 increases the transformation activity of Tax whereas the targeted inhibition of Pin1 significantly suppressed the Tax-mediated cell transformation. Hence, our current data provide the evidence that Pin1 plays a critical role in the post-translational regulation of HTLV-1 Tax.

Materials and methods

Cells. HTLV-1-transformed cells and T-lymphocytes were maintained in RPMI supplemented with 10% fetal calf serum, 2 μ M L-glutamine and penicillin/streptomycin. 293T cells were maintained in DMEM supplemented with 10% fetal calf serum, 2 μ M L-glutamine and penicillin/streptomycin. Mouse T-lymphocyte CTLL-2 cells were kindly provided by Dr. Masahiro Fujii (Niigata University, Japan) and maintained in RPMI supplemented with 10% fetal calf serum, 1 nM IL-2, 50 nM 2-ME, 2 μ M L-glutamine and penicillin/streptomycin.

Transfection and luciferase assay. Transient transfections were carried out using Effectene Transfection Reagent (Qiagen). Luciferase assays have been described previously [9].

RT-PCR. Total RNA was isolated using the RNeasy Mini kit (Qiagen). RT-PCR was performed using the Takara one-step RT-PCR kit, following the manufacturers' instructions.

* Corresponding authors. Fax: +81 3 5285 1165 (N. Yamamoto).
E-mail addresses: aryo@nih.go.jp (A. Ryo), nyama@nih.go.jp (N. Yamamoto).

Protein degradation assay. Protein degradation assays were performed as described previously [10]. Briefly, cycloheximide (100 $\mu\text{g/ml}$) was added to the medium 24 h after cell transfection, and the cells were harvested at different time points.

In vitro and in vivo protein binding assays. GST pull-down and co-immunoprecipitation assay were carried out as described previously [4].

Cell cycle analyses. Cell cycle was analyzed for DNA content using FACSCalibur (Becton Dickinson Bioscience). Cells were stained with propidium iodide (50 $\mu\text{g/ml}$) after RNase treatment as described previously [11].

Colony formation assay. Colony formation assays were performed with CTLL-2 cells infected with retrovirus carrying pMRX-ires-blst-Tax and/or pMRX-ires-puro-Pin1, and pMRX-ires-blst-Tax and/or pSuper-retro-puro-Pin1 siRNA in soft agar media using a CytoSelect 96-well cell transformation assay kit (Cell Biolabs) according to the manufacturer's instructions.

Results

Pin1 increases HTLV-1 Tax-mediated transactivation

To examine whether Pin1 influences Tax-mediated transcriptional activation, 293T cells were transiently transfected with luciferase reporter constructs, HTLV-1 LTR- or NF- κ B-Luc in the absence or presence of Tax and/or Pin1. As expected, the expression of Tax increased the activation of both the HTLV-1 LTR and NF- κ B (Fig. 1A and B, lane 2). In contrast, the expression of Pin1 had no significant effect upon the viral LTR and NF- κ B (lane 3). Interestingly, the co-expression of Tax and Pin1 produced a significant increase in the reporter activity for both HTLV-1 LTR- and NF- κ B-Luc, indicating that Pin1 increases Tax-mediated transcriptional activation (lane 4). These data were further confirmed in HTLV-1-transformed Hut 102 cells expressing endogenous Tax (Fig. 1C). Hut 102 cells infected with a retroviral vector carrying Pin1 siRNA decreased the HTLV-1 LTR luciferase activity compared with cells infected with control siRNA. These data thus demon-

strate that Pin1 enhances Tax-mediated transactivation in HTLV-1-transformed cells.

Pin1 overexpression facilitates the protein stability of HTLV-1 Tax

Next, we sought to examine the expression of Pin1 in HTLV-1-transformed cells and T-lymphocytes (Fig. S1A). Pin1 was found to be highly expressed in Tax-expressing HTLV-1-transformed cells M8166, Hut 102, MT-1, MT-2 and MT-4 compared with Tax-non-expressing HTLV-1-transformed cells ATL-43Tb(-) and T-lymphocytes Jurkat, Molt-4 and CEM cells. To further confirm this contention, we performed Western blot analysis and RT-PCR using 293T/Pin1 siRNA cells transfected with Pin1 and Tax. Pin1 significantly increased the protein expression of Tax in a dose-dependent manner (Fig. S1B) but the Tax mRNA levels showed no significant change (Fig. S1C). These results suggest that Pin1 regulates the expression of the Tax protein via a post-translational mechanism.

To analyze whether Pin1 can stabilize the Tax protein, we performed a protein degradation assay by treating cells with cycloheximide (CHX). First, 293T cells stably expressing either control or Pin1 siRNA cells were transiently co-transfected with Tax and HA-LacZ as an internal control (Fig. 2A). Cycloheximide was then added 24 h post-transfection. Cells were collected at 0, 2, 4, 6 or 8 h and Western blot analyses were performed for Tax, Pin1 and HA-LacZ. This experiment revealed that the protein stability of Tax was significantly reduced in 293T/Pin1 siRNA cells compared with control cells, indicating that Pin1 indeed enhances the protein stability of Tax. Consistent with this result, the stability of Tax was found to be restored by Pin1 overexpression in 293T/Pin1 siRNA cells (Fig. 2B).

Two different pathways, proteasome- and lysosome-dependent, are principally responsible for intracellular protein degradation [12]. To address whether Tax degradation is mediated by either pathway, we performed parallel experiments using either the proteasome inhibitor MG-132 or the lysosome inhibitor NH_4Cl (Fig. S2A). Treatment with NH_4Cl significantly inhibited the rapid degradation of Tax in 293T/Pin1 siRNA cells, whereas the treat-




Fig. 1. Pin1 enhances HTLV-1 Tax-mediated transcriptional activation. (A,B) 293T cells were transiently transfected with plasmids expressing Tax, Pin1 and the reporter constructs HTLV-1 LTR- (A) or NF- κ B-Luc (B). (C) Hut 102 cells were infected with either control or Pin1 siRNA molecules using the pSuper-Retro-puro-vector and then transiently transfected with HTLV-1 LTR-Luc. Forty-eight hours post-transfection, cells were collected and luciferase activities were measured. Luciferase values were adjusted for transfection efficiency using RSV β -galactosidase. (D) Western blot analysis of Hut 102 cells was performed for Tax, Pin1 and tubulin.




Fig. 2. Pin1 overexpression inhibits both the degradation and the ubiquitination of Tax. (A,B) 293T cells stably expressing control siRNA or Pin1 siRNA molecules were transfected with Tax and HA-LacZ (A). 293T/Pin1 siRNA cells were transfected with empty vector or Pin1, Tax and HA-LacZ (B). Cells were treated with cycloheximide (CHX) after 24 h, and harvested at the indicated time points. This was followed by Western blotting analysis with anti-Tax, Pin1 and HA antibodies. The data from the quantitative analyses are shown in the graphs. (C) 293T cells were transfected with either empty vector or Tax in the absence or presence of Myc-Ub. Whole cell lysates were immunoprecipitated with anti-Tax or anti-Myc and immunoblotted with these same antibodies.

ment with MG-132 did not prolong the protein half-life of Tax compared with DMSO control. Additional lysosome inhibitors (leupeptin and chloroquine) further confirmed that the protein degradation of Tax is lysosome-dependent (Fig. S2B).

Pin1 overexpression inhibits the ubiquitination of Tax

To explore the effects of Pin1 upon the ubiquitination of Tax immunoprecipitation analyses of 293T/Pin1 siRNA cells transfected with Tax and/or Pin1 in the absence or presence of ubiquitin revealed that Pin1 overexpression blocks the ubiquitination of Tax (Fig. 2C). In an additional experiment to examine the importance of Pin1 in the suppression of Tax ubiquitination, HTLV-1-transformed Hut 102 cells were treated with the Pin1 inhibitor Juglone or infected with retroviral Pin1 siRNA and processed for immunoblot analysis with anti-Tax antibody which allow the detection of both wild type and ubiquitinated Tax (Fig. S3). The results indicated an increase in the level of polyubiquitinated Tax resulting from the blockage of Pin1. Our data thus confirm that Pin1 suppresses the destabilization and also the ubiquitination of Tax.

Pin1 interacts with Tax during the mitotic phase

The interaction between Tax and Pin1 was determined by GST pull-down assay. The results demonstrate that GST-Pin1, but not

GST interacts with Tax in cell lysates derived from DMSO control cells (Fig. 3A). Of interest, this interaction was significantly increased when cells had been treated with nocodazole (M-phase blocker), but not with hydroxyurea (G1-S-phase blocker), suggesting that cell cycle arrest at mitotic phase facilitates this interaction.

The results of a co-immunoprecipitation assay provide further evidence for the interaction between Pin1 and Tax (Fig. 3B). Hut 102 cells were incubated with or without nocodazole to induce mitotic arrest and immunoprecipitated with either control IgG or anti-Pin1 antibody. The results demonstrate that a significant interaction between Pin1 and Tax occurs at the mitotic phase. The mitotic arrest of cell cycle with nocodazole was determined by the level of cyclin B1 (Fig. 3B) and flow cytometry analysis (Fig. 3C), respectively. In addition, the interaction between Pin1 and Tax was significantly decreased by the treatment with alkaline phosphatase (AP), suggesting that Pin1 binds to only phosphorylated Tax (Fig. S4A). A parallel analysis of Tax and Pin1 binding was performed to test whether either the binding or catalytic activity of Pin1 is necessary for the interaction between Pin1 and Tax. We used 293T/Pin1 siRNA cells transfected with Tax and either empty vector, Pin1 wild type or the Pin1 mutants W34A (WWdomain mutant) and K63A (PPIase domain mutant) (Fig. S4B). The results demonstrate that the WW domain of Pin1 is required for the binding to Tax.




Fig. 3. Pin1 physically interacts with phosphorylated Tax in the mitotic phase *in vitro* and *in vivo*. (A) 293T cells were transfected with either empty vector or Tax and treated with hydroxyurea (HU) or nocodazole (NOC). Cell lysates were prepared, subjected to a pull-down with purified GST or GST-Pin1 and immunoblotted with anti-Tax and GST antibodies. (B) Hut 102 cells were treated with or without NOC. Whole cell lysates were immunoprecipitated with IgG control or anti-Pin1 antibody and then immunoblotted with anti-Tax and anti-Pin1 antibodies. (C) Hut 102 cells treated with or without NOC were fixed in 70% ethanol, stained with propidium iodide (PI) and their cell cycle distribution was analyzed by flow cytometry. (D) 293T cells were transfected with Myc₆-Tax wild type or the Tax S160A mutant for 48 h. Cell lysates were prepared, pulled-down with purified GST or GST-Pin1 and immunoblotted with anti-Myc and GST antibodies. A Western blot for Tax and tubulin is also shown.

The HTLV-1 Tax Ser160-Pro motif is important for the interaction with Pin1 and subsequent protein stabilization by Pin1

To identify the region of Tax that binds to Pin1, we generated several Tax deletion mutants (Fig. S5A). Results of the GST pull-down assay shown in Fig. S5B indicate that Pin1 binds to Tax in the region between amino acids 157 and 190. Pin1 binds to only phosphorylated Ser/Thr-Pro motifs within its target proteins [1,13]. Since there is only single site of Ser/Thr-Pro motif (Ser160-Pro161) between amino acids 157 and 190 in Tax, we introduced a site-specific mutation into Ser160 site by substitution of Ala for Ser (S160A). GST pull-down analysis revealed that Pin1 does not bind to Tax S160A, indicating that Pin1 binds to phosphorylated Ser160-Pro motif of Tax (Fig. 3D). In addition, cycloheximide analysis demonstrated that Pin1 fails to stabilize the S160A mutant of Tax (Fig. S6A). Mutant S160A decreased the transcription of both HTLV-1 LTR and NF- κ B by 50% compared with wild type Tax, suggesting that the phosphorylation of Tax on Ser-160-Pro motif indeed plays a role in regulating the transactivation of HTLV-1 LTR (Figs. S6B and C).

Taken together, these data suggest that the direct interaction between Pin1 and Tax via the Ser 160-Pro motif suppresses the degradation of Tax and thereby enhances its transcriptional activity.

Pin1 promotes Tax-mediated transformation in CTLL-2 cells

Cellular transformation assay was performed using the mouse T-lymphocytes CTLL-2 cells, which are interleukin (IL)-2 dependent cells to explore whether Pin1 can regulate Tax-mediated transformation. Results showed that CTLL-2 cells infected with retroviral

Tax alone showed increased their transformation whereas Pin1 alone had no detectable effect (Fig. 4A). Significantly, co-infection with the retroviral Tax and Pin1 vectors resulted in an increase in transformation, suggesting that Pin1 positively affects the Tax-mediated transformation of CTLL-2 cells. We found by Western blot analysis that Tax expression was stabilized in the presence of Pin1.

A parallel assay was performed to further confirm the importance of Pin1 for Tax-mediated transformation using CTLL-2 cells infected with retroviral vectors expressing either control or Pin1 siRNA and Tax. The results showed that the suppression of Pin1 significantly decreased the transformation efficiency of Tax (Fig. 4B). Taken together, these results indicate that Pin1 plays a positive role in the induction of Tax-mediated transformation via its stable interaction with HTLV-1 Tax protein.

Discussion

The peptidyl prolyl isomerase Pin1 regulates a variety of cellular processes, including cell growth, cell cycle progression and cellular stress responses [14,15] and is linked to the progression of several diseases, including cancer, Alzheimer's disease and asthma [1,13,16,17]. In this regard, it is of interest that in recent studies Pin1 has also been shown to play an important role in virus-related diseases [18,19]. Of interest, Pelopenese et al. reported that Pin1 interacts with the HTLV-1 Tax which is a key factor in leukemogenesis and modulates its activation of NF- κ B [20]. In agreement with this study, we also show that Pin1 binds to phosphorylated Tax and positively regulates the stabilization of Tax, thus promoting Tax-mediated transformation. In addition, we identified a novel phosphorylation site on Ser160 of Tax and showed that it is targeted




Fig. 4. Pin1 promotes the transformation of CTLL-2 cells by Tax. CTLL-2 mouse T-lymphocytes were infected with retroviruses expressing Tax and/or Pin1 (A) and control or Pin1 siRNA, and Tax (B) and incubated in soft agar media for 6–8 days. The formation of colonies was detected with the plate reader using a 485/520 nm filter set. A Western blot analysis for Pin1 and Tax is also shown. Asterisk means the value of Student's *t*-test ($p < 0.001$).

by Pin1-mediated prolyl isomerization by a mapping of Tax binding region to Pin1.

It was recently reported that, by phosphoryl mapping of Tax that both positive and negative phosphorylation signals for this protein result in the maintenance of an "active" subfraction, suggesting the importance of phosphorylation in the regulation of Tax activity [21]. However, it has not been well characterized how the activity of Tax is further regulated by phosphorylation in the cells. Our data demonstrate that Pin1 fails to stabilize a Tax mutant with alanine substitution at Ser160 (S160A), suggesting that the interaction between Pin1 and Tax is critical for the protein stability of Tax. Similarly, it has been demonstrated previously that Pin1 directly binds to phosphorylated cyclin D1 that has been phosphorylated by glycogen synthase kinase-3 β (GSK-3 β) and thereby prevents its nuclear export and ubiquitin-mediated degradation of cyclin D1 [22]. Pin1 also targets the phosphorylated Thr254-Pro motif of NF- κ B p65 and inhibits the binding of p65 and I κ B, which subsequently prevents its degradation by a ubiquitin-mediated pathway [10].

Intracellular protein stabilization is mainly regulated by the ubiquitin-proteasome pathway [23]. Several studies have been shown that Tax is ubiquitinated and physically interacts with the proteasome [24–26]. Of interest, Chiari et al. reported that Tax is not degraded by ubiquitination and that Tax conjugation to ubiquitin in fact mediates a non-proteolytic function of this protein [24]. Our current data suggest that the degradation of Tax is accomplished by a ubiquitin-dependent lysosomal pathway. The degradation of Tax was blocked by the treatment with the lysosome inhibitors NH₄Cl, leupeptin and chloroquine, but not by the proteasome inhibitors MG-132, MG-115 and lactacystin. Importantly, we observed that Pin1 overexpression inhibits the ubiquitination of Tax, further indicating that Pin1 prevents Tax degradation via the ubiquitin-lysosome pathway. Marques et al. previously reported the ubiquitin-dependent lysosomal degradation of the 3-hydroxy-nonenal (HNE)-modified protein in lens epithelial cells [27]. The authors in this study speculated that the ubiquitin-conjugating system may serve as a common mechanism for recognizing various

types of modified or damaged proteins. These ubiquitinated proteins can then be degraded by either the proteasome or through lysosomes although the mechanisms underlying the different fates of these ubiquitinated proteins remain unclear.

Because the HTLV-1 Tax protein is essential for the cellular transformation as well as viral replication [7], it was important from a clinical perspective to identify the mechanisms underlying the activities of this protein. To elucidate the physiological role of Pin1 in the regulation of Tax, we performed a colony transformation assay using CTLL-2 primary mouse T-lymphocytes. Our results demonstrate that Pin1 promotes Tax-mediated cellular transformation and also stabilizes the Tax protein.

In conclusion, we herein demonstrated a novel regulatory mechanism for HTLV-1 Tax that is mediated via Pin1-catalyzed-phosphorylation-dependent prolyl isomerization. Phosphorylation of Tax at Ser160-Pro motif promotes its interaction with Pin1 during the mitotic phase of cell cycle, which stabilizes the Tax protein by inhibiting its ubiquitination and thereby promotes malignant transformation. Further studies will be required to identify the specific kinase(s) responsible for phosphorylation of the Ser160-Pro Pin1 binding motif of Tax. Our present analyses suggest that the targeting of Pin1 may offer a new insight into the pathogenesis and treatment of HTLV-1 related diseases.

Acknowledgments

This study was supported in part by grants from the Japanese Ministries of Education, Culture, Sports, Science and Technology (20390136, 13226027, 14406009 and 1941075) Health, Labour and Welfare (H18-005) and Human Health Science (H19-001) to N.Y. and A.R.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.bbrc.2009.02.024.

References

- [1] K.P. Lu, Y.C. Liou, X.Z. Zhou, Pinning down proline-directed phosphorylation signaling, *Trends Cell Biol.* 12 (2002) 164–172.
- [2] L. Bao, A. Kimzey, G. Sauter, J.M. Sowardski, K.P. Lu, D.G. Wang, Prevalent overexpression of prolyl isomerase Pin1 in human cancers, *Am. J. Pathol.* 164 (2004) 1727–1737.
- [3] J. Kuramochi, T. Arai, S. Ikeda, J. Kumagai, H. Uetake, K. Sugihara, High Pin1 expression is associated with tumor progression in colorectal cancer, *J. Surg. Oncol.* 94 (2006) 155–160.
- [4] A. Ryo, A. Hirai, M. Nishi, Y.C. Liou, K. Perrem, S.C. Lin, H. Hirano, S.W. Lee, I. Aoki, A suppressive role of the prolyl isomerase Pin1 in cellular apoptosis mediated by the death-associated protein Daxx, *J. Biol. Chem.* 282 (2007) 36671–36681.
- [5] B.J. Poiesz, F.W. Ruscetti, A.F. Gazdar, P.A. Bunn, J.D. Minna, R.C. Gallo, Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma, *Proc. Natl. Acad. Sci. USA* 77 (1980) 7415–7419.
- [6] M. Matsuoka, Human T-cell leukemia virus type I and adult T-cell leukemia, *Oncogene* 22 (2003) 5131–5140.
- [7] T. Akagi, H. Ono, K. Shimotohno, Characterization of T cells immortalized by Tax1 of human T-cell leukemia virus type 1, *Blood* 86 (1995) 4243–4249.
- [8] O.J. Semmes, K.T. Jeang, Mutational analysis of human T-cell leukemia virus type I Tax: regions necessary for function determined with 47 mutant proteins, *J. Virol.* 66 (1992) 7183–7192.
- [9] S.J. Jeong, M. Radonovich, J.N. Brady, C.A. Pise-Masison, HTLV-1 Tax induces a novel interaction between p65/RelA and p53 that results in inhibition of p53 transcriptional activity, *Blood* 104 (2004) 1490–1497.
- [10] A. Ryo, F. Suizu, Y. Yoshida, K. Perrem, Y.C. Liou, G. Wulf, R. Rottapel, S. Yamaoka, K.P. Lu, Regulation of NF- κ B signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA, *Mol. Cell* 12 (2003) 1413–1426.
- [11] S.J. Jeong, A. Dasgupta, K.J. Jung, J.H. Um, A. Burke, H.U. Park, J.N. Brady, PI3K/AKT inhibition induces caspase-dependent apoptosis in HTLV-1-transformed cells, *Virology* 370 (2008) 264–272.
- [12] T. Hideshima, J.E. Bradner, D. Chauhan, K.C. Anderson, Intracellular protein degradation and its therapeutic implications, *Clin. Cancer Res.* 11 (2005) 8530–8533.
- [13] A. Ryo, Y.-C. Liou, K.P. Lu, G. Wulf, Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer, *J. Cell Sci.* 116 (2003) 773–783.
- [14] P. Rudrabhatla, Y.L. Zheng, N.D. Amin, S. Kesavapany, W. Albers, H.C. Pant, Pin1 dependent prolyl isomerization modulates the stress induced phosphorylation of high molecular weight neurofilament protein (NF-H), *J. Biol. Chem.* (2008) 26737–26747.
- [15] P. Zacchi, M. Gostissa, T. Uchida, C. Salvagno, F. Avolio, S. Volinia, Z. Ronai, G. Blandino, C. Schneider, G. Del Sal, The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults, *Nature* 419 (2002) 853–857.
- [16] P.J. Lu, G. Wulf, X.Z. Zhou, P. Davies, K.P. Lu, The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein, *Nature* 399 (1999) 784–788.
- [17] Z.J. Shen, S. Esnault, L.A. Rosenthal, R.J. Szakaly, R.L. Sorkness, P.R. Westmark, M. Sandor, J.S. Malter, Pin1 regulates TGF- β 1 production by activated human and murine eosinophils and contributes to allergic lung fibrosis, *J. Clin. Invest.* 118 (2008) 479–490.
- [18] R. Pang, T.K. Lee, R.T. Poon, S.T. Fan, K.B. Wong, Y.L. Kwong, E. Tse, Pin1 interacts with a specific serine-proline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis, *Gastroenterology* 132 (2007) 1088–1103.
- [19] K. Watashi, M. Khan, V.R. Yedavalli, M.L. Yeung, K. Strebler, K.T. Jeang, Human immunodeficiency virus-1 replication and regulation of APOBEC3G by peptidyl prolyl isomerase Pin1, *J. Virol.* (2008) 9928–9936.
- [20] J.-M. Peloponese Jr., J. Yasunaga, T. Kinjo, K. Watashi, K.-T. Jeang, Peptidylproline cis-trans isomerase Pin1 interacts with HTLV-1 Tax and modulates its activation of NF- κ B, *J. Virol.* (2009) (JVI.01824-08).
- [21] S.S. Durkin, M.D. Ward, K.A. Fryrear, O.J. Semmes, Site-specific phosphorylation differentiates active from inactive forms of the human T-cell leukemia virus type 1 Tax oncoprotein, *J. Biol. Chem.* 281 (2006) 31705–31712.
- [22] Y.C. Liou, A. Ryo, H.K. Huang, P.J. Lu, R. Bronson, F. Fujimori, T. Uchida, T. Hunter, K.P. Lu, Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes, *Proc. Natl. Acad. Sci. USA* 99 (2002) 1335–1340.
- [23] A. Herschko, A. Ciechanover, The ubiquitin system, *Annu. Rev. Biochem.* 67 (1998) 425–479.
- [24] E. Chiari, I. Lamsoul, J. Lodewick, C. Chopin, F. Bex, C. Pique, Stable ubiquitination of human T-cell leukemia virus type 1 tax is required for proteasome binding, *J. Virol.* 78 (2004) 11823–11832.
- [25] J.M. Peloponese Jr., H. Iha, V.R. Yedavalli, A. Miyazato, Y. Li, K. Haller, M. Benkirane, K.T. Jeang, Ubiquitination of human T-cell leukemia virus type 1 tax modulates its activity, *J. Virol.* 78 (2004) 11686–11695.
- [26] R. Rousset, C. Desbois, F. Bantignies, P. Jalinot, Effects on NF- κ B/p105 processing of the interaction between the HTLV-1 transactivator Tax and the proteasome, *Nature* 381 (1996) 328–331.
- [27] C. Marques, P. Pereira, A. Taylor, J.N. Liang, V.N. Reddy, L.I. Szwedra, F. Shang, Ubiquitin-dependent lysosomal degradation of the HNE-modified proteins in lens epithelial cells, *FASEB J.* 18 (2004) 1424–1426.



ELSEVIER

FEBS Letters

journal homepage: www.FEBSLetters.org

Requirement for microtubule integrity in the SOCS1-mediated intracellular dynamics of HIV-1 Gag

Mayuko Nishi^{a,b}, Akihide Ryo^{a,b,*}, Naomi Tsurutani^c, Kenji Ohba^a, Tatsuya Sawasaki^d, Ryo Morishita^d, Kilian Perrem^e, Ichiro Aoki^b, Yuko Morikawa^c, Naoki Yamamoto^{a,*}.

^a AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, Japan 162-8640, Japan

^b Department of Pathology, Yokohama City University School of Medicine, 3-9 Fuku-ura, Kanazawa-ku, Yokohama 236-0004, Japan

^c Kitasato Institute for Life Sciences, Kitasato University, Shirokane 5-9-1, Minato-ku, Tokyo 108-8641, Japan

^d Cell Free Science and Research Center, Ehime University, Ehime 790-8577, Japan

^e CSIRO, P.O. Box 225, Dickson ACT 2602, Australia

ARTICLE INFO

Article history:

Received 8 December 2008

Revised 16 March 2009

Accepted 18 March 2009

Available online 25 March 2009

Edited by Kaspar Locher

Keywords:

HIV

Host factor

Suppressor of cytokine signaling 1

Microtubule

Ubiquitin

Trafficking

ABSTRACT

Suppressor of cytokine signaling 1 (SOCS1) is a recently identified host factor that positively regulates the intracellular trafficking and stability of HIV-1 Gag. We here examine the molecular mechanism by which SOCS1 regulates intercellular Gag trafficking and virus particle production. We find that SOCS1 colocalizes with Gag along the microtubule network and promotes microtubule stability. SOCS1 also increases the amount of Gag associated with microtubules. Both nocodazole treatment and the expression of the microtubule-destabilizing protein, stathmin, inhibit the enhancement of HIV-1 particle production by SOCS1. SOCS1 facilitates Gag ubiquitination and the co-expression of a dominant-negative ubiquitin significantly inhibits the association of Gag with microtubules. We thus propose that the microtubule network plays a role in SOCS1-mediated HIV-1 Gag transport and virus particle formation.

Structured summary:

MINT-7014185: Gag (uniprotkb:P05888) and SOCS1 (uniprotkb:O15524) colocalize (MI:0403) by cosedimentation (MI:0027)

MINT-7014239: Cullin 2 (uniprotkb:Q13617) physically interacts (MI:0218) with RelA (uniprotkb:Q04206), RBX1 (uniprotkb:P62877), SOCS1 (uniprotkb:O15524), elongin B (uniprotkb:Q15369) and elongin C (uniprotkb:Q15370) by pull-down (MI:0096)

MINT-7014046: gag (uniprotkb:P05888), SOCS1 (uniprotkb:O15524) and tubulin alpha (uniprotkb:Q13748) colocalize (MI:0403) by fluorescence microscopy (MI:0416)

MINT-7014269: tubulin alpha (uniprotkb:Q13748) physically interacts (MI:0218) with Gag (uniprotkb:P05888) by anti tag coimmunoprecipitation (MI:0007)

MINT-7014036: tubulin alpha (uniprotkb:Q13748) and SOCS1 (uniprotkb:O15524) colocalize (MI:0403) by fluorescence microscopy (MI:0416)

MINT-7014201: Cullin 2 (uniprotkb:Q13617) physically interacts (MI:0218) with RBX1 (uniprotkb:P62877), SOCS1 (uniprotkb:O15524), elongin B (uniprotkb:Q15369) and elongin C (uniprotkb:Q15370) by pull-down (MI:0096)

MINT-7014257: Gag (uniprotkb:P05888) physically interacts (MI:0218) with Ubiquitin (uniprotkb:P62988) by anti tag coimmunoprecipitation (MI:0007)

MINT-7014221: Cullin 2 (uniprotkb:Q13617) physically interacts (MI:0218) with Gag (uniprotkb:P05888), elongin C (uniprotkb:Q15370), elongin B (uniprotkb:Q15369), SOCS1 (uniprotkb:O15524) and RBX1 (uniprotkb:P62877) by pull-down (MI:0096)

© 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Abbreviations: HIV, human immunodeficiency virus; SOCS1, Suppressor of cytokine signaling 1; KIR, kinase inhibitory region; MTOC, microtubule organizing center; Ub, ubiquitin; VLP, virus-like particle

* Corresponding authors. Address: AIDS Research Center, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama, Tokyo 208-0011, Japan (A. Ryo). Fax: +81 42 563 6291.

E-mail addresses: aryo@nih.go.jp (A. Ryo), nyama@nih.go.jp (N. Yamamoto).

1. Introduction

The human immunodeficiency virus 1 (HIV-1) employs multi-step and multi-factorial processes for producing progeny viruses during infection [1,2]. Virus must utilize the intrinsic transport machinery of the infected host cells to enable the active transport

of viral proteins [3,4]. Several recent studies have identified cellular factors that modulate HIV-1 Gag trafficking and localization. These include AP-3 δ , POSH, HP68, GGA and Trim22 [5–9]. Moreover, phosphatidylinositol-(4,5)-bisphosphate (PIP2) has been shown to control the targeting of Gag to the plasma membrane [10]. These findings point to a critical role of host cell factors in Gag assembly and release, but the precise molecular functions of these factors and the specific timing of their roles in this process remain largely unknown.

We recently reported that the suppressor of cytokine signaling 1 (SOCS1) is an inducible host factor during HIV-1 infection and plays an important role in the intracellular trafficking of Gag to the plasma membrane, resulting in the efficient production of HIV-1 particles [11]. Moreover, we have further shown that the function of SOCS1 in Gag trafficking and HIV-1 particle production is not principally due to the suppression of interferon/cytokine signaling, but is mediated via its interaction with the HIV-1 Gag polyprotein [11]. Importantly, the targeted depletion of SOCS1 results in the mistargeting and degradation of Gag in lysosomes, leading to a significant decrease in virus particle production [11].

In our current study, we have utilized SOCS1 as a molecular tool to further reveal the molecular mechanisms underlying the intracellular transport of HIV-1 Gag during viral infection. We reveal from our findings that SOCS1 regulates the Gag trafficking process via the microtubule-dependent cellular machinery. Furthermore, we find that Gag is also regulated by a ubiquitin signaling pathway which is accompanied by Gag ubiquitination. These findings shed new light on the mechanisms involved in the intracellular transport of HIV-1 Gag and provide important clues for the design of future novel therapeutic interventions against AIDS and related disorders.

2. Materials and methods

2.1. Antibodies

Antibodies (Abs) and fluorescent reagents were obtained from the following sources: rabbit polyclonal anti-myc (A-14) and rabbit polyclonal anti-SOCS1 (H-93) Abs (Santa Cruz Biotechnology); rabbit polyclonal anti-SOCS1 (Zymed Laboratories); mouse monoclonal anti-FLAG (M2), anti- α -tubulin, anti-acetylated- α -tubulin and anti- γ -tubulin Abs (Sigma, St. Louis, MO); rabbit polyclonal anti-stathmin antibody (Calbiochem); mouse monoclonal anti-myc antibody (9B11, Cell Signaling Technology); mouse monoclonal anti-cytokeratin 7, cytokeratin 18, vimentin and HIV-p24 Ab (Dako Cytomation). Immunoblotting, immunoprecipitation and immunofluorescent analyses were performed as described previously [11].

2.2. Plasmids and sequences

Expression constructs for SOCS1 have been described previously [12]. HIV-1 Gag constructs have also been described previously [13]. Stathmin cDNA was amplified by RT-PCR from a human kidney cDNA library using the primers 5'-AGCAAGCTTGCCACCATTGGCTTCTTCTGATATCCAGG-3' and 5'-GACGGATCCGTCAGCTTCAGTCTCGTCAG-3' and then subcloned into the pcDNA3.1 vector. pcDNA3.1-myc-ubiquitin and its mutants were generated by PCR as described previously [14]. The siRNA sequences were as follows: SOCS1-siRNA, GGCCAGAACCTTCTCTCTT; control-siRNA, TCGTATGTTGTGGAATT. All expression constructs were validated by sequencing.

2.3. Microtubule-associated protein spin-down assays

Microtubule-associated proteins were collected using a microtubule-associated protein spin-down assay kit (Cytoskeleton,

BK029) according to the manufacturer's instructions. Briefly, 293T cells were lysed in 0.5 ml of PEM buffer (80 mM PIPES, pH 6.9, 0.3% Triton X-100, 1 mM EGTA, 1 mM GTP, 1 mM MgCl₂) supplemented with 1 mM phenylmethylsulfonyl fluoride, 5 μ g/ml leupeptin, 2 μ g/ml aprotinin, 1 mM sodium orthovanadate, and 5 mM NaF. Cell lysates were incubated with taxol-stabilized microtubules, followed by ultracentrifuge at 100000 \times g for 40 min at 25 $^{\circ}$ C.

2.4. Cell culture

The 293T, COS-1, COS-7, HeLa and HOS cell lines and mouse embryonic fibroblasts (MEFs) were cultured in DMEM supplemented with 10% FBS. SOCS1^{-/-} MEF cells were cultured as described previously [12].

2.5. In vitro interaction analysis

The in vitro interaction between HIV-1 Gag and the SOCS1-E3 complex was analyzed as follows: ¹⁴C-labeled recombinant proteins (SOCS1, elongin B/C, Rbx1, biotin labeled cullin 2, and HIV-1 Gag) were synthesized in a wheat germ cell-free system as described previously [15]. The synthesized proteins were subsequently incubated in 120 μ l of reaction buffer (50 mM Tris-HCl, pH 7.6, 50 mM MgCl₂, 500 mM CH₃COOK, 0.1 mM DTT and 1 mg/ml BSA) and streptavidin magnetic beads (Promega, Madison, WI) at 23 $^{\circ}$ C for 1 h. The precipitated proteins were then washed three times with reaction buffer and subjected to autoradiography.

3. Results

3.1. SOCS1 aligns with microtubule forming fibrous structures

SOCS1 has been shown previously to localize at both the perinuclear region and the microtubule organizing center (MTOC) [16]. This finding indicated the possible involvement of the microtubule network in the regulation of Gag by SOCS1. We thus addressed whether the Gag transport system is in fact mediated by microtubule integrity and if SOCS1 enhances this process. Immunofluorescent analysis with α -tubulin antibodies revealed that endogenous SOCS1 forms punctate structures that align with the microtubule network (Fig. 1A). Importantly, these signals were completely abolished when the cells were stained with anti-SOCS1 antibodies that had been pre-absorbed with recombinant SOCS1 protein, confirming the specificity of this antibody (Fig. 1B). Parallel experiments revealed that SOCS1 does not colocalize with other cytoskeletal components such as actin or intermediate filaments (Fig. 1C).

3.2. SOCS1 promotes microtubule stability

Given our finding that SOCS1 can tightly associate with microtubules, we next addressed whether SOCS1 affects microtubule stability. Stabilized microtubules are frequently enriched in tubulin that has undergone post-translational modifications such as acetylation [17]. We found that the high expression of SOCS1 results in higher amounts of acetylated microtubules in three different cell lines when compared with control cells (Fig. 2A) and that this trend is dose-dependent in COS-7 cells (Fig. 2B). On the other hand, SOCS1^{-/-} mouse embryonic fibroblasts (MEFs) exhibited lower levels of acetylated α -tubulin compared with wild-type MEFs (Fig. 2C). These results indicate that SOCS1 does indeed contribute to the stabilization of microtubules.

Mammalian cells usually possess a population of microtubules that are resistant to the depolymerization effects of microtubule disorganizing reagents. We thus addressed whether SOCS1 impacts




Fig. 1. SOCS1 colocalizes with microtubule forming fibrous structures. (A) COS-1 cells were fixed with 3% formaldehyde followed by 100% cold methanol, and then co-immunostained with polyclonal antibodies targeting SOCS1 (red) and monoclonal antibodies targeting α -tubulin (green). Cells were then analyzed by confocal microscopy. Scale bar, 10 μ m. (B) COS-1 cells were immunostained with anti- α -tubulin monoclonal antibodies together with anti-SOCS1 polyclonal antibodies that had either been non-absorbed or pre-absorbed with GST-SOCS1 proteins. This was followed by confocal microscopy. Scale bar, 10 μ m. (C) COS-1 cells were fixed with 3% formaldehyde followed by 100% cold methanol, then co-immunostained with polyclonal antibodies targeting SOCS1 (red) and monoclonal antibodies targeting various cytoskeletal components (green). Cells were then analyzed by confocal microscopy.

upon this property in this subpopulation of microtubules in COS-7 cells. The cells were transfected with either SOCS1 or control vector and then treated with 1 μ M colchicine for 12 h to fully depolymerize the microtubules. Immunostaining with antibodies against acetylated α -tubulin showed that the SOCS1 expressing cells contained more polymerized microtubules compared with the control cells (Fig. 2D). These results indicate that SOCS1 might contribute to the microtubule stability required for Gag trafficking via this network.

3.3. SOCS1 enhances the association of HIV-1 Gag with microtubules

We next investigated the sub-cellular localization of HIV-1 Gag with SOCS1 and microtubules. COS-1 cells were transfected with Gag-GFP and after 24 h were fixed with 3% formaldehyde, followed by 100% cold methanol. The cells were then immunostained with anti-SOCS1 and anti- α -tubulin antibodies. Consistent with our earlier results, confocal microscopic analysis revealed that SOCS1 can form dotted filamentous structures in the cytoplasm along the

microtubules, and that HIV-1 Gag colocalizes with these SOCS1 puncta (Fig. 3A).

To next determine whether cellular SOCS1 and Gag can together mechanically bind microtubules, and thus whether SOCS1 expression has any impact upon the interaction between Gag and microtubules, we performed microtubule pull-down analysis. 293T cells were transfected with either Gag-FLAG, myc-SOCS1, or a combination of these two plasmids, and the lysates from these transfected cells were subsequently incubated with taxol-stabilized microtubules and centrifuged to pellet the microtubule-associated proteins. The pellet fractions were then subjected to immunoblotting using either anti-myc or anti-FLAG antibodies. SOCS1 was found to be co-sedimented with microtubules irrespective of whether Gag had been co-transfected (Fig. 3B). The quantities of microtubule-bound Gag in the pellet fraction, however, were significantly increased when SOCS1 was co-transfected (Fig. 3B). These results together indicate that SOCS1 is itself a microtubule binding protein that may also mediate the interaction between HIV-1 Gag and microtubules.




Fig. 2. SOCS1 enhances microtubule stability. (A) COS-7, HeLa or HOS cells were transfected with either empty vector or myc-SOCS1 for 48 h. Cell lysates were then subjected to immunoblotting analysis with antibodies against α -tubulin, acetylated α -tubulin or SOCS1. (B) COS-7 cells were transfected with various amounts of myc-SOCS1 as in (A). Cell lysates were then subjected to immunoblotting analysis with anti- α -tubulin, anti-acetylated- α -tubulin or anti-myc antibodies. Numerical values below the blots indicate acetylated α -tubulin signal intensities normalized by the unmodified α -tubulin intensity derived by densitometry. (C) Exponentially growing wild-type MEFs or SOCS1^{-/-} MEFs were lysed and the cell lysates were immunoblotted with antibodies against α -tubulin, acetylated α -tubulin or SOCS1. (D) COS-7 cells were co-transfected with empty vector or myc-SOCS1, and then treated with colchicine (1 μ M) for 12 h to depolymerize the microtubules. Cells were then fixed and immunostained with both anti-acetylated- α -tubulin (green) or anti-myc (red) antibodies and then stained with 4',6-diamino-2-phenylindole (DAPI, blue), followed by confocal microscopy. Scale bar, 10 μ m.




Fig. 3. SOCS1 enhances HIV-1 Gag associated with microtubules. (A) COS-1 cells transiently transfected with HIV-1 Gag-GFP were co-immunostained with antibodies targeting endogenous SOCS1 (red) and microtubules (α -tubulin, blue). The inset indicates the area shown at higher magnification in the right hand panels which reveal the colocalization of Gag-GFP with SOCS1 along the microtubules. Scale bar, 10 μ m. (B) Cosedimentation of SOCS1 and HIV-1 Gag with polymerized microtubules. 293T cells were transfected with the indicated plasmids for 36 h. Cell lysates were then incubated with taxol-stabilized microtubules or control buffer and separated into precipitate (PPT) and supernatant fractions. Precipitate fractions were subjected to immunoblotting analysis with anti-myc or anti-FLAG antibodies.

3.4. Microtubule integrity is required for SOCS1 to function in HIV-1 particle formation

Our results shown above indicated that SOCS1 mediates the association of HIV-1 Gag with the microtubule networks. We next examined therefore whether SOCS1-mediated Gag trafficking, and the resultant HIV-1 particle production, are dependent upon an intact microtubule network. 293T cells were transfected with the

HIV-1 molecular clone pNL4-3 and co-transfected with either empty vector alone or myc-SOCS1. After 24 h, the cells were washed with PBS and then cultured in the presence or absence of nocodazole for a further 6 h. Subsequent measurement of the p24 antigen levels in the cell supernatant by ELISA revealed nocodazole treatment significantly inhibited the enhancement of HIV-1 particle production in SOCS1-transfected cells more dramatically than in vector control transfected cells, and that this was

dose-dependent (Fig. 4A). Consistent with these results also, SOCS1 localization, i.e. from a dotted filamentous structure along the

microtubules to diffuse and larger aggregations in the cytoplasm (Fig. 4B). The use of trypan blue dye exclusion confirmed that cell viability was not affected by the nocodazole treatment (Fig. 4C).




Fig. 4. Microtubule integrity is required for SOCS1 to function in HIV-1 particle formation. (A) 293T cells were transfected with pNL4-3, and co-transfected with either empty vector alone (Vector) or myc-SOCS1. After 24 h, cells were washed with PBS and then cultured with fresh media including the indicated concentrations of nocodazole for 6 h. Supernatant p24 antigen levels were measured by p24 ELISA. The data shown are the average \pm S.D. of three independent experiments. $P < 0.05$, by the Student's *t*-test. (B and C) Mislocalization of SOCS1 in cells treated with nocodazole. COS-1 cells were treated with vehicle only or with nocodazole (2 μ g/ml) for 6 h. Cells were then fixed and immunostained with both anti-SOCS1 (red) and anti- α -tubulin (green) antibodies, followed by confocal microscopy (B). Scale bar, 10 μ m. The numbers of viable cells were calculated by trypan blue dye exclusion (C). (D) COS-1 cells transfected with Gag-GFP were treated with vehicle only or with nocodazole (2 μ g/ml) for 6 h followed by immunostaining with anti- α -tubulin (red) antibody. Scale bar, 10 μ m. (E and F) 293T cells were transfected with pNL4-3 and either vector or SOCS1, and co-transfected with various amounts of stathmin. At 36 h after transfection, cell lysate and supernatant virus-like particle (VLP) were processed for immunoblotting analysis with anti-p24, anti-PARP, anti- β -actin or anti-stathmin antibodies (E). VLP p24 Gag signal intensities, derived by densitometry, are shown in (F).




Fig. 5. SOCS1 enhances the ubiquitination of HIV-1 Gag and this affects the association of Gag with the microtubules. (A) Schematic representation of SOCS1 mutants. (B) 293T cells were transfected with pNL4-3 and co-transfected with control vector, wild-type SOCS1 (WT), SOCS1-F59D mutant or ΔSOCS-box mutant. After 48 h, the p24 levels in the cell supernatants were measured by ELISA. (C) HIV-1 Gag associates with the ubiquitin ligase complex of SOCS1 in vitro. ¹⁴C-labeled proteins (SOCS1, biotin labeled Cullin2, elongin B/C, Rbx1, HIV-1 Gag and RelA) were synthesized using a wheat germ cell-free system. Purified proteins were incubated in the indicated combinations for 1 h and subjected to co-purification with streptavidin magnetic beads. Captured proteins were then separated by SDS-PAGE followed by autoradiography. (D) 293T cells were co-transfected with Gag-FLAG, myc-tagged ubiquitin, and either empty vector (Vector) or SOCS1 expression construct. After 48 h, cells were lysed and denatured by boiling them in 1% SDS lysis buffer and diluted to RIPA buffer conditions, and Gag-FLAG proteins were immunoprecipitated (IP) with anti-FLAG antibody and processed for anti-myc immunoblotting to detect ubiquitinated Gag. Ubn, polyubiquitinated. Numerical values below blot indicates the relative levels of ubiquitinated Gag normalized by the amount of total Gag. (E) 293T cells were co-transfected with Gag-FLAG, myc-tagged ubiquitin, and either control-siRNA or SOCS1-siRNA. After 48 h, cell lysates were immunoprecipitated with anti-FLAG antibody and processed for anti-myc immunoblotting to detect ubiquitinated Gag. Ubn, polyubiquitinated. Numerical values below blot indicates the relative levels of ubiquitinated Gag normalized by the amount of total Gag. (F) 293T cells were transfected with Gag-GFP and SOCS1, and co-transfected with either myc-Ub-WT or myc-Ub^ΔGG. After 24 h, cell lysates were harvested and subjected to immunoprecipitation analysis with anti-α-tubulin antibody or non-immunized mouse IgG (IgG) followed by immunoblotting analysis with the indicated antibodies. (G) 293T cells were transfected with Gag-FLAG and SOCS1, and co-transfected with either myc-Ub-WT or myc-Ub^ΔGG. After 24 h, cell lysates were harvested and then incubated with taxol-stabilized microtubules (+MT) or control buffer (-MT), and separated into precipitate and supernatant fractions. Precipitate fractions were collected and then subjected to immunoblotting analysis with either anti-FLAG or anti-α-tubulin (microtubule) antibodies.

Furthermore, a parallel experiment revealed that the Gag-GFP puncta formed larger aggregations in the cytoplasm upon nocodazole treatment (Fig. 4D).

To further delineate the role of microtubule integrity in HIV-1 particle formation, we next performed experiments in which we co-transfected SOCS1 and pNL4-3 with or without the microtubule-destabilizing protein stathmin. Stathmin expression efficiently blocked the effects of SOCS1 upon HIV-1 particle formation in a dose-dependent manner (Fig. 4E and F). Cell viability was not strongly affected as revealed by immunoblotting analysis of either poly (ADP-ribose) polymerase (PARP) or β -actin (Fig. 4E). Our findings together indicate therefore that microtubule integrity may be required for SOCS1 to function in Gag assembly and release.

3.5. SOCS1 facilitates the ubiquitination of HIV-1 Gag

Our previous study has revealed that the SOCS-box of SOCS1 is required for both HIV-1 particle production and the enhancement of Gag association with microtubules [11]. The mechanism by which SOCS1 inhibits cytokine signaling is mediated by the inhibition of kinase activity through its N-terminal kinase inhibitory region (KIR) [18]. We next examined whether SOCS1 mutants lacking the function of either KIR (SOCS1-F59D) or SOCS-box (Δ SOCS) affected virus particle production. Our ELISA results indicate that the SOCS-box deletion mutant (Δ SOCS) of SOCS1 fails to promote virus production, whereas the KIR mutant, F59D, of SOCS1 partially enhances HIV-1 particle production when co-transfected with pNL4-3 in 293T cells (Fig. 5A and B). These data again suggest that the function of SOCS1 in HIV-1 particle production is not principally due to the suppression of interferon/cytokine signaling, but is mediated by its direct interaction with the HIV-1 Gag via the function of the SOCS-box.

The SOCS-box-mediated function of SOCS1 is chiefly exerted via its ubiquitin ligase activity [19]. Indeed, several reports have demonstrated that Gag ubiquitination is related to its membrane association and particle release, although the function of HIV-1 Gag ubiquitination remains unclear [20,21]. We thus explored the possibility that SOCS1 modulates the ubiquitination of HIV-1 Gag, leading to enhanced virus particle formation. We initially examined the specific interaction of HIV-1 Gag with the SOCS1-E3 ligase complex. Purified SOCS1 and its E3 component proteins (biotinylated-Cullin 2, elongin B/C and Rbx1) in addition to HIV-1 Gag were synthesized in a wheat germ cell-free system and then subjected to pull-down assays using streptavidin coated magnetic beads. We found that Gag was co-purified with a SOCS1-E3 complex comprising SOCS1-elongin B/C-Rbx1-Cullin2 in a similar manner to RelA, a previously reported SOCS1 binding protein (Fig. 5C, left). Significantly, in the absence of SOCS1, both elongin B and C were not co-purified with Cullin 2 probably due to the unsteady condition of the E3 complex without SOCS1, and the amount of bound Gag was also reduced (Fig. 5C, right). These results indicate that the SOCS1-E3 complex associates with HIV-1 Gag and may promote its ubiquitination.

We next addressed whether SOCS1 affects the ubiquitination of HIV-1 Gag. Immunoprecipitation analysis with cells co-transfected with Gag-FLAG and myc-tagged ubiquitin, with or without SOCS1 co-transfection, revealed that SOCS1 overexpression significantly enhances the ubiquitination of the Gag protein (Fig. 5D). In contrast, the targeted depletion of SOCS1 by siRNA significantly reduced the amount of ubiquitinated Gag (Fig. 5E). These results indicate that SOCS1 could indeed be a potent ubiquitin ligase for HIV-1 Gag.

To clarify the biological significance of Gag ubiquitination via SOCS1, we performed an experiment using a dominant-negative ubiquitin construct lacking two C-terminal glycines (residues 75–

76). This mutant ubiquitin (Ub Δ GG) cannot become conjugated to target substrates, but can bind noncovalently to ubiquitin interacting domains [14]. By immunoprecipitation analysis we revealed that the levels of HIV-1 Gag associated with microtubules were significantly reduced in cells expressing Ub Δ GG, as compared with those expressing wild-type ubiquitin (Ub-WT) (Fig. 5F). This trend was further revealed by a microtubule sedimentation experiment showing that the expression of Ub Δ GG reduced the amount of Gag associated with microtubules when compared with the expression of Ub-WT (Fig. 5G). These results together indicate a link between ubiquitin signaling and the microtubule-mediated Gag dynamics involved with HIV-1 particle formation.

4. Discussion

In our current study, we report that microtubule integrity is required for SOCS1 to facilitate Gag trafficking and virus particle production. We demonstrate from our experiments that (1) SOCS1 colocalizes with HIV-1 Gag along microtubules; (2) both SOCS1 and HIV-1 Gag are co-purified with microtubules and SOCS1 can augment the association of Gag with microtubules; (3) an intact microtubule network is required for the function of SOCS1 during Gag trafficking; (4) SOCS1 facilitates Gag ubiquitination; and (5) Gag association with the microtubules is significantly reduced when a dominant-negative Ub mutant is overexpressed. These results together indicate that SOCS1 can regulate the trafficking and stability of HIV-1 Gag via the microtubule-related cellular machinery, which may be in turn enhanced by Gag ubiquitination.

SOCS1 was identified initially as a negative regulator of signaling downstream of cytokines [22–24] and has been shown to localize at both the perinuclear region and the microtubule organizing center (MTOC) in cells [16]. We show from our current data that SOCS1 also forms dotted filamentous structures in the cytoplasm emanating from the perinuclear region, including the MTOC, to the cell periphery. A recent report has also indicated that Gag colocalizes at the MTOC with HIV-1 RNA and is subsequently transported to the cell periphery [25]. These observations together indicate that SOCS1 might facilitate the trafficking of HIV-1 Gag from the MTOC toward the plasma membrane by utilizing the intrinsic transport machinery of infected host cells.

The plus-end directed transport system along the microtubules could provide a means for the targeting of virus capsid proteins to the site of virus assembly and budding in the vicinity of the plasma membrane [26]. This ante-grade transport system is utilized by several viruses, such as herpes simplex virus type 1 (HSV-1), vaccinia virus and African swine fever virus (ASFV) [26–29]. Significantly, we have demonstrated in our present study that HIV-1 can utilize the microtubule-dependent transport mechanism, which may in turn be enhanced by SOCS1. Consistent with this notion, Leblanc et al. have demonstrated previously using a monoclonal antibody raised against unprocessed Gag that intracellular Gag puncta can travel along microtubules [30]. Our current microtubule pull-down analyses also clearly indicate that SOCS1 associates with Gag on microtubules and can enhance this interaction. This in turn might accelerate the intracellular trafficking of Gag to the plasma membrane along these structures, although the topological details are still unknown. Consistent with this observation, a plus-end microtubule motor KIF4 has been shown previously to associate with HIV-1 Gag and to enhance Gag trafficking [31,32]. These results further demonstrate the relevance of microtubule network in the trafficking of the HIV-1 Gag.

The involvement of the microtubule cytoskeleton in Gag assembly and HIV-1 particle egress is somewhat controversial [3,26,33,34]. However, several reports have presented convincing data to indicate the importance of this network in HIV-1 assembly

and propagation [3,35,36]. Our current study further demonstrates that the microtubule depolymerizing reagent, nocodazole, or the expression of microtubule-destabilizing protein stathmin, significantly inhibits the enhancement of HIV-1 particle production by SOCS1, suggesting a possible role of the microtubule network in regular HIV-1 particle production.

Our previous report indicated that the targeted depletion of SOCS1 results in the prominent perinuclear accumulations of HIV-1 Gag in 293T cells [11]. Our current study shows that nocodazole treatment or stathmin expression only slightly affects Gag release in non-SOCS1 overexpressing cells. This difference might be attributable to the following two possibilities. First, SOCS1 may affect Gag at multiple points during trafficking and assembly, and a critical point could be prior to the microtubule-mediated events that can be affected by nocodazole or stathmin. Second, there are multiple pathways to the delivery of exogenously expressed Gag protein from the cytoplasm to the plasma membrane in addition to microtubule-directed transport. Furthermore, we are currently uncertain whether the Gag association with microtubules is mediated by other microtubule binding proteins in cooperation with SOCS1, or whether SOCS1 directly associates with HIV-1 Gag on the microtubules. Further careful analysis must be performed to elucidate these possibilities.

Acknowledgements

We thank Drs. A. Yoshimura, Y. Tanaka, K.P. Lu and J.A. Komano for providing materials, and R. Kimura, S. Takahama and H. Soeda for their excellent technical assistance. This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (20390136, 13226027, 14406009 and 1941075) and Human Health Science (H19-001) to N.Y. and A.R.

References

- [1] Sorin, M. and Kalpana, G.V. (2006) Dynamics of virus–host interplay in HIV-1 replication. *Curr. HIV Res.* 4, 117–130.
- [2] Trkola, A. (2004) HIV–host interactions: vital to the virus and key to its inhibition. *Curr. Opin. Microbiol.* 7, 407–411.
- [3] Naghavi, M.H. and Goff, S.P. (2007) Retroviral proteins that interact with the host cell cytoskeleton. *Curr. Opin. Immunol.* 19, 402–407.
- [4] Lama, J. and Planelles, V. (2007) *Retrovirology* 4, 52.
- [5] Dong, X. et al. (2005) AP-3 directs the intracellular trafficking of HIV-1 Gag and plays a key role in particle assembly. *Cell* 120, 663–674.
- [6] Perlman, M. and Resh, M.D. (2006) Identification of an intracellular trafficking and assembly pathway for HIV-1 gag. *Traffic* 7, 731–745.
- [7] Alroy, I. et al. (2005) The trans-Golgi network-associated human ubiquitin-protein ligase POSH is essential for HIV type 1 production. *Proc. Natl. Acad. Sci. USA* 102, 1478–1483.
- [8] Barr, S.D., Smiley, J.R. and Bushman, F.D. (2008) The interferon response inhibits HIV particle production by induction of TRIM22. *PLoS Pathog.* 4, e1000007.
- [9] Joshi, A., Garg, H., Nagashima, K., Bonifacino, J.S. and Freed, E.O. (2008) GGA and Arf proteins modulate retrovirus assembly and release. *Mol. Cell* 30, 227–238.
- [10] Ono, A., Ablan, S.D., Lockett, S.J., Nagashima, K. and Freed, E.O. (2004) Phosphatidylinositol (4, 5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane. *Proc. Natl. Acad. Sci. USA* 101, 14889–14894.
- [11] Ryo, A. et al. (2008) SOCS1 is an inducible host factor during HIV-1 infection and regulates the intracellular trafficking and stability of HIV-1 Gag. *Proc. Natl. Acad. Sci. USA* 105, 294–299.
- [12] Ryo, A. et al. (2003) Regulation of NF- κ B signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. *Mol. Cell* 12, 1413–1426.
- [13] Wagner, R., Graf, M., Bieler, K., Wolf, H., Grunwald, T., Foley, P. and Uberla, K. (2000) Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. *Hum. Gene Ther.* 11, 2403–2413.
- [14] Stang, E., Blystad, F.D., Kazacic, M., Bertelsen, V., Brodahl, T., Raiborg, C., Stenmark, H. and Madhus, I.H. (2004) Cbl-dependent ubiquitination is required for progression of EGF receptors into clathrin-coated pits. *Mol. Biol. Cell* 15, 3591–3604.
- [15] Sawasaki, T., Ogasawara, T., Morishita, R. and Endo, Y. (2002) A cell-free protein synthesis system for high-throughput proteomics. *Proc. Natl. Acad. Sci. USA* 99, 14652–14657.
- [16] Vuong, B.Q. et al. (2004) SOCS-1 localizes to the microtubule organizing complex-associated 20S proteasome. *Mol. Cell Biol.* 24, 9092–9101.
- [17] Westermann, S. and Weber, K. (2003) Post-translational modifications regulate microtubule function. *Nat. Rev. Mol. Cell Biol.* 4, 938–947.
- [18] Kobayashi, T. and Yoshimura, A. (2005) Keeping DCs awake by putting SOCS1 to sleep. *Trends Immunol.* 26, 177–179.
- [19] Kile, B.T., Schulman, B.A., Alexander, W.S., Nicola, N.A., Martin, H.M. and Hilton, D.J. (2002) The SOCS box: a tale of destruction and degradation. *Trends Biochem. Sci.* 27, 235–241.
- [20] Jager, S., Gottwein, E. and Krausslich, H.G. (2007) Ubiquitination of human immunodeficiency virus type 1 Gag is highly dependent on Gag membrane association. *J. Virol.* 81, 9193–9201.
- [21] Strack, B., Calistri, A., Accola, M.A., Palu, G. and Gottlinger, H.G. (2000) A role for ubiquitin ligase recruitment in retrovirus release. *Proc. Natl. Acad. Sci. USA* 97, 13063–13068.
- [22] Naka, T. et al. (1997) Structure and function of a new STAT-induced STAT inhibitor. *Nature* 387, 924–929.
- [23] Endo, T.A. et al. (1997) A new protein containing an SH2 domain that inhibits JAK kinases. *Nature* 387, 921–924.
- [24] Starr, R. et al. (1997) A family of cytokine-inducible inhibitors of signalling. *Nature* 387, 917–921.
- [25] Poole, E., Strappe, P., Mok, H.P., Hicks, R. and Lever, A.M. (2005) HIV-1 Gag–RNA interaction occurs at a perinuclear/centrosomal site: analysis by confocal microscopy and FRET. *Traffic* 6, 741–755.
- [26] Greber, U.F. and Way, M. (2006) A superhighway to virus infection. *Cell* 124, 741–754.
- [27] Benboudjema, L., Mulvey, M., Gao, Y., Pimplikar, S.W. and Mohr, I. (2003) Association of the herpes simplex virus type 1 Us11 gene product with the cellular kinesin light-chain-related protein PAT1 results in the redistribution of both polypeptides. *J. Virol.* 77, 9192–9203.
- [28] Dohner, K. and Sodeik, B. (2005) The role of the cytoskeleton during viral infection. *Curr. Top. Microbiol. Immunol.* 285, 67–108.
- [29] Jouvenet, N., Monaghan, P., Way, M. and Wileman, T. (2004) Transport of African swine fever virus from assembly sites to the plasma membrane is dependent on microtubules and conventional kinesin. *J. Virol.* 78, 7990–8001.
- [30] Leblanc, J.J., Perez, O. and Hope, T.J. (2008) Probing the structural states of human immunodeficiency virus type 1 pr55gag by using monoclonal antibodies. *J. Virol.* 82, 2570–2574.
- [31] Tang, Y., Winkler, U., Freed, E.O., Torrey, T.A., Kim, W., Li, H., Goff, S.P. and Morse 3rd, H.C. (1999) Cellular motor protein KIF-4 associates with retroviral Gag. *J. Virol.* 73, 10508–10513.
- [32] Martinez, N.W., Xue, X., Berro, R.G., Kreitzer, G. and Resh, M.D. (2008) Kinesin KIF4 regulates intracellular trafficking and stability of the human immunodeficiency virus type 1 Gag polyprotein. *J. Virol.* 82, 9937–9950.
- [33] Finzi, A., Orthwein, A., Mercier, J. and Cohen, E.A. (2007) Productive human immunodeficiency virus type 1 assembly takes place at the plasma membrane. *J. Virol.* 81, 7476–7490.
- [34] Jouvenet, N., Neil, S.J., Bess, C., Johnson, M.C., Virgen, C.A., Simon, S.M. and Bieniasz, P.D. (2006) Plasma membrane is the site of productive HIV-1 particle assembly. *PLoS Biol.* 4, e435.
- [35] Jolly, C., Mitar, I. and Sattentau, Q.J. (2007) Requirement for an intact T-cell actin and tubulin cytoskeleton for efficient assembly and spread of human immunodeficiency virus type 1. *J. Virol.* 81, 5547–5560.
- [36] Handley, M.A., Paddock, S., Dall, A. and Pangniban, A.T. (2001) Association of Vpu-binding protein with microtubules and Vpu-dependent redistribution of HIV-1 Gag protein. *Virology* 291, 198–207.

An HIV protease inhibitor, ritonavir targets the nuclear factor-kappaB and inhibits the tumor growth and infiltration of EBV-positive lymphoblastoid B cells

Md. Zahidunnabi Dewan^{1,2}, Mariko Tomita³, Harutaka Katano⁴, Norio Yamamoto¹, Sunjida Ahmed¹, Michiko Yamamoto⁵, Tetsutaro Sata⁴, Naoki Mori^{3*} and Naoki Yamamoto^{1,2*}

¹Department of Molecular Virology, Graduate School, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan

²AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan

³Division of Molecular Virology and Oncology, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan

⁴Department of Pathology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan

⁵Division of Safety Information on Drug, National Institute of Health Sciences, Food and Chemicals, Setagaya-ku, Tokyo 158-8501, Japan

Epstein-Barr Virus (EBV)-associated immunoblastic lymphoma occurs in immunocompromised patients such as those with AIDS or transplant recipients after primary EBV infection or reactivation of a preexisting latent EBV infection. In the present study, we evaluated the effect of ritonavir, an HIV protease inhibitor, on EBV-positive lymphoblastoid B cells *in vitro* and in mice model. We found that it induced cell-cycle arrest at G₁-phase and apoptosis through down-regulation of cell-cycle gene cyclin D2 and anti-apoptotic gene survivin. Furthermore, ritonavir suppressed transcriptional activation of NF-κB in these cells. Ritonavir efficiently prevented growth and infiltration of lymphoma cells in various organs of NOD/SCID/γc^{null} mice at the same dose used for treatment of patients with AIDS. Our results indicate that ritonavir targets NF-κB activated in tumor cells and shows anti-tumor effects. These data also suggest that this compound may have promise for treatment or prevention of EBV-associated lymphoproliferative diseases that occur in immunocompromised patients.
© 2008 Wiley-Liss, Inc.

Key words: ritonavir; LCLs; NF-κB; NOG mice

Epstein-Barr virus (EBV) is a ubiquitous human γ herpes virus that establishes a latent infection more than 90% of adults worldwide.¹ Immunocompromised individuals such as those with AIDS or transplant recipients are at increased risk for developing aggressive EBV-associated lymphoproliferative diseases. EBV is associated with malignant diseases, including Burkitt's lymphoma,^{1,2} nasopharyngeal carcinoma^{3,4} and immunoblastic B cell lymphoma of immunosuppressed individuals. Infection of primary B cells with EBV results in transformation with growth of the cells in tight clumps and immortalization of the cells. These immortalized B cells have an immunoblastic morphology and express each of the EBV-encoded small RNAs (EBERs), EBV nuclear antigen (EBNAs) and latent membrane proteins (LMPs).^{2,5} EBERs have oncogenic potential through inhibition of PKR.⁶ EBNA-2 is a transactivator that up-regulates expression of cellular genes and LMPs. LMP-1 may mediate proliferative and survival effects not only in EBV-transformed B lymphocytes but also in these malignancies that occur long after primary infection. Many immunocompromised patients with EBV-associated immunoblastic lymphoma have tumors at extranodal sites such as the brain, lung, or gastrointestinal tract. The prognosis of EBV-associated lymphomas is very poor for patients with irreversible immunosuppression and treatment options are limited.

Despite the diversity in clinical manifestations of hematopoietic malignancies, strong and constitutive nuclear factor-kappaB (NF-κB) activation was reported to be a unique and common characteristic of malignant cells.^{7,8} In resting cells, NF-κB is sequestered as an inactive precursor by association with inhibitory IκBs in the cytoplasm. On stimulation, IκBs are rapidly phosphorylated, ubiquitinated and degraded by a proteasome-dependent pathway allowing active NF-κB to translocate into the nucleus where it can

activate the expression of a number of genes.⁹ LMP-1 is an oncoprotein that constitutively activates NF-κB to induce B cell proliferation.⁷ Lymphoblastoid cell lines (LCLs) express high level of the antiapoptotic proteins BCL-2, BCL-xL, c-IAP1, Bfl-1 and c-FLIP the targets of NF-κB.^{10,11} NF-κB activation has been connected with multiple processes of oncogenesis including control of apoptosis, cell-cycle, differentiation and cell migration,⁹ and therefore, inhibition of NF-κB was suggested to be a useful strategy for cancer therapy.^{12–20} It has been also reported that inhibition of NF-κB in EBV-associated lymphomas results in induction of apoptosis.²¹ Therefore, targeting the NF-κB pathway and inhibition of NF-κB activity is a logical strategy for treating EBV-associated lymphomas.

Ritonavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, has been successfully used in clinical treatments of HIV infection, with patients exhibiting a marked decrease in HIV viral load and a subsequent increase in CD4⁺ T-cell counts.^{22–25} Evidence of other effects by ritonavir on cellular proteases, such as the cysteine proteases cathepsin D and E, was presented in the drug's original description, albeit at concentrations >500-fold above the concentration required for inhibition of HIV protease.²⁶ Protease inhibitors have also been shown to directly affect cell metabolism, interfere with host or fungal proteases and block T-cell activation and dendritic-cell function.^{27,28} Ritonavir has been shown to inhibit the chymotrypsin-like activity of the 20S proteasome, and it activates the chymotrypsin-like activity of the 26S proteasome conversely.^{27,29,30} Ritonavir also has been reported to inhibit the transactivation of NF-κB induced by activators such as TNFα, HIV-1 Tat protein and the human herpesvirus 8 protein ORF74.³¹ It is possible that inhibition of NF-κB activation by ritonavir is linked to additional pathways other than inhibition of proteasome.³¹ Protease inhibitors also have been shown to have direct antiangiogenic and antitumor activity.^{31,32} Recently, we reported that ritonavir inhibits growth and infiltration of ATL cells through targeting NF-κB.²⁰

Grant sponsors: Ministry of Education, Science and Culture, The Ministry of Health, Labor and Welfare, Human Health Science of Japan.

Md. Zahidunnabi Dewan's current address is: Department of Pathology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA.

Md. Zahidunnabi Dewan and Mariko Tomita contributed equally to this work.

*Correspondence to: AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan. Fax: 8135-285-1165. E-mail: nyama@nih.go.jp (or) Division of Molecular Virology and Oncology, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan. Fax: 81-98-895-1410. E-mail: n-mori@med.u-ryukyu.ac.jp.

Received 14 July 2008; Accepted after revision 2 September 2008

DOI 10.1002/ijc.23993

Published online 15 September 2008 in Wiley InterScience (www.interscience.wiley.com).